Open an account

Fulcrum Therapeutics

FULC · NASDAQ

$3.72+$0.02 (+0.54%)TodayMarket closed ·
Prev close $3.70

About FULC

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.

Employees
55
Headquarters
Cambridge, Massachusetts
Listed
Jul 18, 2019
Sector
Health Care
Industry
Pharmaceuticals
Website
fulcrumtx.com

FULC key statistics

Market cap
283.83M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.49M
Volume
757.12K
Open price
$3.71
High today
$3.75
Low today
$3.70
52 Week high
$15.74
52 Week low
$2.83

Fulcrum Therapeutics (FULC) at a glance

As of Oct 20, 2026, Fulcrum Therapeutics (FULC) shares are priced at $3.72, giving the company a market cap of 283.83M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.70 and $3.75. The current price is 0.7% above the day's low and 0.8% below its high.

Volume so far is 757.12K shares, below the average of 1.49M shares a day.

Over the past year Fulcrum Therapeutics has ranged from $2.83 to $15.74, and now sits 7% of the way up that range.

Fulcrum Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.22 per share against an estimate of -$0.2244.

The average analyst price target is $7.75, 108.4% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

11%of 9 analyst ratings say Buy
  • Buy11.1%
  • Hold55.6%
  • Sell33.3%
Price target · 7 analystsAvg $7.75
Low
$3.03
Now
$3.72
High
$25.20

FULC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 7.8% on average.

  1. Q3 FY24: reported -$0.35 per share against an estimate of -$0.4137
  2. Q4 FY24: reported -$0.31 per share against an estimate of -$0.3279
  3. Q1 FY25: reported -$0.28 per share against an estimate of -$0.2999
  4. Q2 FY25: reported -$0.28 per share against an estimate of -$0.2958
  5. Q3 FY25: reported -$0.31 per share against an estimate of -$0.2996
  6. Q4 FY25: reported -$0.31 per share against an estimate of -$0.3153
  7. Q1 FY26: reported -$0.25 per share against an estimate of -$0.3041
  8. Q2 FY26: reported -$0.22 per share against an estimate of -$0.2244

FULC news

  • Press releasePRNewswire

    Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?

  • Press releaseNewsfile

    Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

  • Press releaseNewsfile

    Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights

  • Press releaseNewsfile

    Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations

  • Press releaseNewsfile

    Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations

  • Press releaseNewsfile

    Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation

  • Press releasePRNewswire

    Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders?

  • Press releaseNewsfile

    Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations

Similar companies

Companies in the same industry as Fulcrum Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.